DUPONT MERCK GENERIC CIMETIDINE WILL BE DISTRIBUTED BY ENDO LABS
Executive Summary
DUPONT MERCK GENERIC CIMETIDINE WILL BE DISTRIBUTED BY ENDO LABS following the expiration on May 17 of SmithKline Beecham's Tagamet patent. DuPont Merck received tentative ANDA approvals on April 29 for 200 mg, 300 mg and 400 mg tablet strengths of the anti-ulcer medication. On May 3, the firm added an approval for an 800 mg tablet. The company announced the establishment of its generic drug subsidiary Endo in March ("The Pink Sheet" March 28, T&G-3).